Healthcare
Summit Therapeutics Inc.(SMMT)
Live Price
Offline$13.75
-2.27% today
1Y Change
-32.56%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $12.50B
- Revenue Growth
- 0.0%
- EPS Growth
- -364.5%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Summit Therapeutics Inc. (SMMT) is a Healthcare stock with a market cap of $12.50B and listed on NASDAQ. The stock last traded around $13.75 and down 32.6% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -364.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -364.5%, free cash flow -127.5% with operating margin 0.0% and ROIC -215.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SMMT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -364.5%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +5.4% | +5.8% | -13.9% |
2026 Feb 23, 2026 | -182.5% | +0.2% | +0.6% | -3.0% |
2025 Oct 20, 2025 | -76.4% | -6.5% | -2.9% | -15.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SMMT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SMMT Max Drawdown
-55.49%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SMMT and SPY.
Company Overview
Summit Therapeutics Inc.
NASDAQ Global Market
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
- Leadership
- Robert W. Duggan
- IPO Date
- Mar 5, 2015
- Employees
- 159
- Street Address
- One Broadway
- Mailing
- Cambridge, MA, 02142
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 514 7149
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 22.9
Growth
- Revenue
- 0.0%
- EPS
- -364.5%
- Free Cash Flow
- -127.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -291.2%
- ROIC
- -215.4%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 7.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.